After the U.S. Food & Drug Administration has requested more information on GlaxoSmithKline PLC’s cervical cancer vaccine Cervarix, the company’s shares fell Monday.
A so-called complete response letter was received by Glaxo - a kind that the U.S. regulator issues when the review of a marketing application file is completed and questions remain to be answered prior to approval.
"We have already started addressing the questions and will be engaged in discussions with the FDA to finalize our responses," said Barbara Howe, GlaxoSmithKline's vice president and director of North American vaccine development.
GlaxoSmithKline shares fell 1.4 percent to 1,305 pence (26.33 dollars; 18.26 euros) on the London Stock Exchange. The company had said earlier that it expected to get the drug, which is expected to become a multibillion-dollar product, to the U.S. market sometime in 2008.
Representatives of the Israeli Defence Ministry responded to recent reports about the possible delivery of S-300 SAM systems from Russia to Syria. Israeli Defence Minister Avigdor Lieberman said that Israel would destroy those systems
Russia is to start supplying S-300 air defence systems to Syria in the near future. The shipments will be conducted free of charge